212 related articles for article (PubMed ID: 2527324)
21. Disruption of ovarian development in alligator embryos treated with an aromatase inhibitor.
Lance VA; Bogart MH
Gen Comp Endocrinol; 1992 Apr; 86(1):59-71. PubMed ID: 1387096
[TBL] [Abstract][Full Text] [Related]
22. Role of aromatization in testosterone-induced inhibition of luteinizing hormone secretion in female turtles, Trachemys scripta.
Tsai PS; Hayes TB; Licht P
Biol Reprod; 1994 Jan; 50(1):144-51. PubMed ID: 8312438
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
24. Blockade of estrogen synthesis with an aromatase inhibitor affects luteal function of the pseudopregnant rat.
Shetty G; Bhatnagar AS; Moudgal NR
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):347-53. PubMed ID: 8541231
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Nishino Y; Schneider MR; Michna H; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
[TBL] [Abstract][Full Text] [Related]
26. Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening.
Kitawaki J; Kim T; Kanno H; Noguchi T; Yamamoto T; Okada H
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):667-70. PubMed ID: 8476780
[TBL] [Abstract][Full Text] [Related]
27. Additive effects of aminoglutethimide, testololactone, and 4-hydroxyandrostenedione as inhibitors of aromatase.
Santner SJ; Rosen H; Osawa Y; Santen RJ
J Steroid Biochem; 1984 Jun; 20(6A):1239-42. PubMed ID: 6748639
[TBL] [Abstract][Full Text] [Related]
28. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Pérez N; Borja J
J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
[TBL] [Abstract][Full Text] [Related]
29. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
[TBL] [Abstract][Full Text] [Related]
30. Effect of aromatase inhibitors on the histology of the cycling rat ovary.
Coney P; Yoshimura Y; Hosoi Y; Bongiovanni A; Wallach E
Gynecol Obstet Invest; 1987; 23(3):177-83. PubMed ID: 3596353
[TBL] [Abstract][Full Text] [Related]
31. [The inhibitory effect of miconazole on aromatase activity for androstenedione in human placental and ovarian preparations].
Yamamoto T; Urabe M; Okada H
Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1379-85. PubMed ID: 3443212
[TBL] [Abstract][Full Text] [Related]
32. The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511.
Kudoh M; Susaki Y; Ideyama Y; Nanya T; Okada M; Shikama H; Fujikura T
J Steroid Biochem Mol Biol; 1995 Sep; 54(5-6):265-71. PubMed ID: 7577709
[TBL] [Abstract][Full Text] [Related]
33. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
Brodie AM; Santen RJ
Crit Rev Oncol Hematol; 1986; 5(4):361-96. PubMed ID: 3094971
[TBL] [Abstract][Full Text] [Related]
34. Aromatase inhibition in the dog. I. Effect on serum LH, serum testosterone concentrations, testicular secretions and spermatogenesis.
Juniewicz PE; Oesterling JE; Walters JR; Steele RE; Niswender GD; Coffey DS; Ewing LL
J Urol; 1988 Apr; 139(4):827-31. PubMed ID: 2451039
[TBL] [Abstract][Full Text] [Related]
35. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
Demers LM; Melby JC; Wilson TE; Lipton A; Harvey HA; Santen RJ
J Clin Endocrinol Metab; 1990 Apr; 70(4):1162-6. PubMed ID: 2156889
[TBL] [Abstract][Full Text] [Related]
36. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
Wing LY; Garrett WM; Brodie AM
Cancer Res; 1985 Jun; 45(6):2425-8. PubMed ID: 3921242
[TBL] [Abstract][Full Text] [Related]
37. A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Tekmal RR; Durgam VR
Cancer Lett; 1997 Sep; 118(1):21-8. PubMed ID: 9310256
[TBL] [Abstract][Full Text] [Related]
38. Reversible inhibition of human placental microsomal aromatase by CGS 18320B and other non-steroidal compounds.
Bullion KA; Osawa Y; Braun DG
Endocr Res; 1990; 16(2):255-67. PubMed ID: 2140551
[TBL] [Abstract][Full Text] [Related]
39. The effects of the aromatase inhibitor delta 1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease.
Dunaif A; Longcope C; Canick J; Badger T; Crowley WF
J Clin Endocrinol Metab; 1985 Apr; 60(4):773-80. PubMed ID: 3919053
[TBL] [Abstract][Full Text] [Related]
40. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Schieweck K; Bhatnagar AS; Matter A
Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
